Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies

Journal of Experimental Medicine

Volumn 210, Issue 6, 2013, Pages 1235-1249

  Diskin, Ron ^a   Klein, Florian ^b   Horwitz, Joshua A ^b   Halper Stromberg, Ariel ^b   Sather, D Noah ^c   Marcovecchio, Paola M ^a   Lee, Terri ^a   West, Anthony P ^a   Gao, Han ^a   Seaman, Michael S ^d   Stamatatos, Leonidas ^c,e   Nussenzweig, Michel C ^b,f   Bjorkman, Pamela J ^f  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

AMPLICON; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENE MUTATION; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 84879523938     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20130221     Document Type: Article

References (38)

1. Adams, P.D., P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, et al. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66: 213-221. http://dx.doi.org/10.1107/S0907444909052925
2. Baba, T.W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L.A. Cavacini, M.R. Posner, H. Katinger, G. Stiegler, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206. http://dx.doi.org/10.1038/72309
3. Baenziger, S., R. Tussiwand, E. Schlaepfer, L. Mazzucchelli, M. Heikenwalder, M.O. Kurrer, S. Behnke, J. Frey, A. Oxenius, H. Joller, et al. 2006. Disseminated and sustained HIV infection in CD34+ cord blood celltransplanted Rag2-/-gamma c-/- mice. Proc. Natl. Acad. Sci. USA. 103: 15951-15956. http://dx.doi.org/10.1073/pnas.0604493103
4. Balazs, A.B., J. Chen, C.M. Hong, D.S. Rao, L. Yang, and D. Baltimore. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 481:81-84. http://dx.doi.org/10.1038/nature10660
5. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760-763. http://dx.doi.org/10.1107/S0907444994003112
6. Denton, P.W., J.D. Estes, Z. Sun, F.A. Othieno, B.L. Wei, A.K. Wege, D.A. Powell, D. Payne, A.T. Haase, and J.V. Garcia. 2008. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5:e16. http://dx.doi.org/10.1371/journal.pmed.0050016
7. Diskin, R., P.M. Marcovecchio, and P.J. Bjorkman. 2010. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat. Struct. Mol. Biol. 17:608-613. http://dx.doi.org/10.1038/nsmb.1796
8. Diskin, R., J.F. Scheid, P.M. Marcovecchio, A.P. West Jr., F. Klein, H. Gao, P.N. Gnanapragasam, A. Abadir, M.S. Seaman, M.C. Nussenzweig, and P.J. Bjorkman. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 334:1289-1293. http://dx.doi.org/10.1126/science.1213782
9. Doria-Rose, N.A., M.K. Louder, Z. Yang, S. O'Dell, M. Nason, S.D. Schmidt, K. McKee, M.S. Seaman, R.T. Bailer, and J.R. Mascola. 2012. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J. Virol. 86:3393-3397. http://dx.doi.org/10.1128/JVI.06745-11
10. Emsley, P., B. Lohkamp, W.G. Scott, and K. Cowtan. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66:486-501. http://dx.doi.org/10.1107/S0907444910007493
11. Hessell, A.J., E.G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D.N. Forthal, W.C. Koff, D.I. Watkins, and D.R. Burton. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433. http://dx.doi.org/10.1371/journal.ppat.1000433
12. Hofman, P., and A.M. Nelson. 2006. The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Curr. Med. Chem. 13:3121-3132. http://dx.doi.org/10.2174/092986706778742891
13. Johnson, P.R., B.C. Schnepp, J.C. Zhang, M.J. Connell, S.M. Greene, E. Yuste, R.C. Desrosiers, and K.R. Clark. 2009. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15:901-906. http://dx.doi.org/10.1038/nm.1967
14. Kabsch, W. 2010. Integration, scaling, space-group assignment and postrefinement. Acta Crystallogr. D Biol. Crystallogr. 66:133-144. http://dx.doi.org/10.1107/S0907444909047374
15. Keele, B.F., E.E. Giorgi, J.F. Salazar-Gonzalez, J.M. Decker, K.T. Pham, M.G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA. 105: 7552-7557. http://dx.doi.org/10.1073/pnas.0802203105
16. Klein, F., A. Halper-Stromberg, J.A. Horwitz, H. Gruell, J.F. Scheid, S. Bournazos, H. Mouquet, L.A. Spatz, R. Diskin, A. Abadir, et al. 2012. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 492:118-122. http://dx.doi.org/10.1038/nature11604
17. Kwong, P.D., R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski, and W.A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:648-659. http://dx.doi.org/10.1038/31405
18. Louie, M., C. Hogan, M. Di Mascio, A. Hurley, V. Simon, J. Rooney, N. Ruiz, S. Brun, E. Sun, A.S. Perelson, et al. 2003. Determining the relative efficacy of highly active antiretroviral therapy. J. Infect. Dis. 187: 896-900. http://dx.doi.org/10.1086/368164
19. Manz, M.G. 2007. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity. 26:537-541. http://dx.doi.org/10.1016/j.immuni.2007.05.001
20. Mascola, J.R., G. Stiegler, T.C. VanCott, H. Katinger, C.B. Carpenter, C.E. Hanson, H. Beary, D. Hayes, S.S. Frankel, D.L. Birx, and M.G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210. http://dx.doi.org/10.1038/72318
21. McCoy, A.J., R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read. 2007. Phaser crystallographic software. J. Appl. Cryst. 40:658-674. http://dx.doi.org/10.1107/S0021889807021206
22. Mehandru, S., B. Vcelar, T. Wrin, G. Stiegler, B. Joos, H. Mohri, D. Boden, J. Galovich, K. Tenner-Racz, P. Racz, et al. 2007. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81:11016-11031. http://dx.doi.org/10.1128/JVI.01340-07
23. Montefiori, D.C. 2005. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12:12: 11.
24. Mouquet, H., L. Scharf, Z. Euler, Y. Liu, C. Eden, J.F. Scheid, A. Halper-Stromberg, P.N. Gnanapragasam, D.I. Spencer, M.S. Seaman, et al. 2012. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA. 109:E3268-E3277. http://dx.doi.org/10.1073/pnas.1217207109
25. Nakamura, K.J., C. Cerini, E.R. Sobrera, L. Heath, M. Sinkala, C. Kankasa, D.M. Thea, J.I. Mullins, L. Kuhn, and G.M. Aldrovandi. 2013. Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. AIDS. 27:337-346. http://dx.doi.org/10.1097/QAD.0b013e32835cadd6
26. Neumann, T., I. Hagmann, S. Lohrengel, M.L. Heil, C.A. Derdeyn, H.G. Kräusslich, and M.T. Dittmar. 2005. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Virology. 333:251-262. http://dx.doi.org/10.1016/j.virol.2004.12.035
27. Sather, D.N., S. Carbonetti, J. Kehayia, Z. Kraft, I. Mikell, J.F. Scheid, F. Klein, and L. Stamatatos. 2012. Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. J. Virol. 86:12676-12685. http://dx.doi.org/10.1128/JVI.01893-12
28. Scheid, J.F., H. Mouquet, N. Feldhahn, B.D. Walker, F. Pereyra, E. Cutrell, M.S. Seaman, J.R. Mascola, R.T. Wyatt, H. Wardemann, and M.C. Nussenzweig. 2009. A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods. 343:65-67. http://dx.doi.org/10.1016/j.jim.2008.11.012
29. Scheid, J.F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 333:1633-1637. http://dx.doi.org/10.1126/science.1207227
30. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622. http://dx.doi.org/10.1038/nm1244
31. Trkola, A., H. Kuster, P. Rusert, V. von Wyl, C. Leemann, R. Weber, G. Stiegler, H. Katinger, B. Joos, and H.F. Günthard. 2008. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J. Virol. 82:1591-1599. http://dx.doi.org/10.1128/JVI.01792-07
32. Vallone, B., A.E. Miele, P. Vecchini, E. Chiancone, and M. Brunori. 1998. Free energy of burying hydrophobic residues in the interface between protein subunits. Proc. Natl. Acad. Sci. USA. 95:6103-6107. http://dx.doi.org/10.1073/pnas.95.11.6103
33. Veazey, R.S., R.J. Shattock, M. Pope, J.C. Kirijan, J. Jones, Q. Hu, T. Ketas, P.A. Marx, P.J. Klasse, D.R. Burton, and J.P. Moore. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343-346. http://dx.doi.org/10.1038/nm833
34. Walker, L.M., S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, et al; Protocol G Principal Investigators. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326:285-289. http://dx.doi.org/10.1126/science.1178746
35. Walker, L.M., M. Huber, K.J. Doores, E. Falkowska, R. Pejchal, J.P. Julien, S.K. Wang, A. Ramos, P.Y. Chan-Hui, M. Moyle, et al; Protocol G Principal Investigators. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 477:466-470. http://dx.doi.org/10.1038/nature10373
36. West, A.P. Jr., R. Diskin, M.C. Nussenzweig, and P.J. Bjorkman. 2012. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA. 109:E2083-E2090. http://dx.doi.org/10.1073/pnas.1208984109
37. Wu, X., Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 329:856-861. http://dx.doi.org/10.1126/science.1187659
38. Zhou, T., I. Georgiev, X. Wu, Z.Y. Yang, K. Dai, A. Finzi, Y.D. Kwon, J.F. Scheid, W. Shi, L. Xu, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 329:811-817. http://dx.doi.org/10.1126/science.1192819